Obesity Surgery

, Volume 20, Issue 6, pp 692–697 | Cite as

Single vs Repeated Treatment with the Intragastric Balloon: A 5-Year Weight Loss Study

  • Jean-Marc DumonceauEmail author
  • Erik François
  • Axel Hittelet
  • Abdel Ilah Mehdi
  • Marie Barea
  • Jacques Deviere
Clinical Research



Saline-filled intragastric balloons (IB) may be inserted for 6 months to promote weight loss. We aimed to assess potential benefits of repeating IB therapy.


One hundred eighteen consecutive subjects (median body mass index, 34.0 kg/m2; interquartile range [IQR], 31.2–36.9) treated with IB were included in a prospective non-randomized multicenter study.


Nineteen (16%) subjects had repeat IB therapy at their own request, either to prolong first treatment (n = 8) or after a IB-free interval (n = 11). Higher weight loss 3 months after first IB insertion independently predicted repeat therapy (P = 0.008). Median weight loss in subjects who had repeat therapy was lower with second vs first IB (9.0 vs 14.6 kg; 30.4% vs 49.3% excess weight [EW]; P = 0.003). Compared to subjects with single treatment (n = 99), those with repeat treatment (n = 19) had greater weight loss at first IB extraction (14.6 vs 11.0 kg; 49.3% vs 30.7% EW; P = 0.026) and 1 year later (12.0 vs 6.0 kg; 40.9% vs 20.8% EW; P = 0.008) but the difference became less than 2 kg starting at 3 years. At final follow-up (4.9 years; IQR, 3.4–6.7), the whole subject population had lost a median of 2.0 kg (IQR, −3.0 to 10.3) or 6.2% EW (IQR, −8.1 to 31.6) and identical proportions of subjects with single/repeat treatment had ≥10% baseline weight loss (26%) or bariatric surgery (32%).


Higher weight loss at 3 months independently predicted repeat IB therapy; weight loss with the second IB was lower compared to first IB. Repeat treatment had no effect on proportions of subjects with ≥10% baseline weight loss or bariatric surgery at final follow-up.


Obesity Gastrointestinal endoscopy Gastric balloon Weight loss 



body mass index


intragastric balloon


interquartile range


last observation carried forward


Potential Conflicts of Interests

The authors declare that they have no conflict of interest.


No funding was obtained for this work.


  1. 1.
    Dumonceau JM. Evidence-based review of the bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18:1611–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30:129–33.CrossRefGoogle Scholar
  3. 3.
    Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17:649–57.CrossRefPubMedGoogle Scholar
  4. 4.
    Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19–27.CrossRefPubMedGoogle Scholar
  5. 5.
    National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res. 1998;6 Suppl 2:51S–209.Google Scholar
  6. 6.
    Zago S, Kornmuller AM, Agagliati D, et al. Benefit from bio-enteric Intra-gastric balloon (BIB) to modify lifestyle and eating habits in severely obese patients eligible for bariatric surgery. Minerva Med. 2006;97:51–64.PubMedGoogle Scholar
  7. 7.
    Lorentz FH. Der konstitutionsindex der frau. Klin Wochenshr. 1929;16:734–6.CrossRefGoogle Scholar
  8. 8.
    Doldi SB, Micheletto G, Perrini MN, et al. Treatment of morbid obesity with intragastric balloon in association with diet. Obes Surg. 2002;12:583–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Francica G, Giardiello C, Iodice G, et al. Ultrasound as the imaging method of choice for monitoring the intragastric balloon in obese patients: normal findings, pitfalls and diagnosis of complications. Obes Surg. 2004;14:833–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Douketis JD, Macie C, Thabane L, et al. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes. 2005;29:1153–67.CrossRefGoogle Scholar
  11. 11.
    Dansinger ML, Tatsioni A, Wong JB, et al. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med. 2007;147:41–50.PubMedGoogle Scholar
  12. 12.
    Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251–64.PubMedGoogle Scholar
  13. 13.
    Machytka E, Klvana P, Hanuskova L, et al. Use of pharmacotherapy for long-term maintenance of weight loss following explantation of intragastric balloon (BIB). Gut. 2007;57:A290.Google Scholar
  14. 14.
    Padwal R, Kezouh A, Levine M, et al. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes. 2007;31:1567–70.CrossRefGoogle Scholar
  15. 15.
    Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;337:1194–9.CrossRefGoogle Scholar
  16. 16.
    Williamson DF. Pharmacotherapy for obesity. JAMA. 1999;281:278–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Melissas J, Mouzas J, Filis D, et al. The intragastric balloon—smoothing the path to bariatric surgery. Obes Surg. 2006;16:897–902.CrossRefPubMedGoogle Scholar
  18. 18.
    Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14:539–44.CrossRefPubMedGoogle Scholar
  20. 20.
    Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14:991–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Evans JD, Scott MH. Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg. 2001;88:1245–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2010

Authors and Affiliations

  • Jean-Marc Dumonceau
    • 1
    • 4
    Email author
  • Erik François
    • 2
  • Axel Hittelet
    • 2
  • Abdel Ilah Mehdi
    • 3
  • Marie Barea
    • 2
  • Jacques Deviere
    • 2
  1. 1.Service of Gastroenterology and HepatologyGeneva University HospitalsGenevaSwitzerland
  2. 2.Department of Gastroenterology and Hepato-PancreatologyErasme University HospitalBrusselsBelgium
  3. 3.Department of Digestive SurgeryErasme University HospitalBrusselsBelgium
  4. 4.Division of Gastroenterology and HepatologyGeneva University HospitalsGenevaSwitzerland

Personalised recommendations